|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 248.90 DKK | +0.10% |
|
+4.10% | -23.86% |
| 07:56pm | Top pharma companies racing to launch a weight-loss pill | RE |
| 07:22pm | NOVO NORDISK : Barclays reaffirms its Neutral rating | ZD |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 17TCr | |||||
| 88TCr | |||||
| 58TCr | |||||
| 41TCr | |||||
| 36TCr | |||||
| 30TCr |
- Stock Market
- Equities
- NOVO B Stock
- Charts Novo Nordisk A/S
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition